GEA Pharma & Healthcare Insight stories
Insight stories
.jpg?h=1350&iar=0&w=2400&rev=1b429cc0c71d46d499711e0731d4a0cd&hash=BB51B496350FA3FA7A4E892151983C5E&mw=3840 "biopharma industry")
Perfusion separators speed up biopharma processes
Small biopharma manufacturing outfits are often the driving force behind the proliferation of innovative medical treatments. GEA is revolutionizing cell harvesting capabilities for these manufacturers with perfusion separators that enable efficiency-optimized continuous processing. For the first time, suitable disk stack separators have been transformed into compact single-use machines saving space, labor and effort while paving the way for increased production output and speed.
Continuous Innovation: How GEA is Leading the Future of Pharmaceutical Manufacturing
From the first ConsiGma® line in 2004 to the launch of CDC Flex today, GEA has been at the forefront of pharmaceutical innovation.
Continuous innovation is our commitment — to our customers, to the industry, and to a better world.
A safer way to produce cancer treatments
As anti-cancer drugs become more powerful and complex, GEA is redefining how to safely freeze-dry these life-saving treatments.
The new F-Gas Regulation and its impact on pharmaceutical freeze-drying
Discover how the new F-Gas Regulation (EU) 2024/573 affects pharmaceutical freeze-drying. Learn about stricter quotas, HFC phase-out, and innovative solutions for reducing environmental impact and energy consumption.
Innovating patient care with aseptic spray drying
At GEA, our commitment to engineering for a better world fuels our pursuit of innovative solutions that enhance patient care and safety. One of our most promising ventures in recent years is aseptic spray drying – a technology that promises to revolutionize pharmaceutical manufacturing.
Saving lives with affordable, accessible vaccines
Millions of babies, children and adults around the world receive vaccinations that protect them against devastating diseases such as diphtheria, measles, polio and whooping cough, which are caused by pathogenic bacteria and viruses.
Advancing pharmaceutical processing, transforming the future, saving lives
GEA and its partners are leading the way toward smaller, more flexible, continuous processing technologies that are transforming the future of pharmaceutical development and manufacturing.
Vaccine production technology plays a vital role in animal disease control
Domestic animal diseases often have a tremendous effect on local and global economies, as well as posing a potential threat to public health. Vaccines can serve as a powerful tool for combating transmission, but quality is key. To aid efforts that move us closer to a disease-free world, GEA provides equipment to assist in the complete production process of these high-quality vaccines.
How continuous manufacturing is redefining the pharmaceutical supply chain
Continuous pharmaceutical manufacturing is no longer a niche trend. It’s already happening. Although implementation and knowledge transfer can be time consuming, early adopters are embarking on a new trajectory of business excellence, benefiting from numerous competitive advantages and staying ahead of the market.
Manufacturing medicines for today and the future
As scientists continue to elucidate the genomic basis of diseases such as cancer, it is becoming increasingly possible to develop different drugs for the same condition and target patients with a specific genetic profile.
Development of new vaccines
GEA, the globally active mechanical and plant engineering company, takes its role in the fight against the coronavirus — and any other — epidemic, extremely seriously. But how do we prove that a vaccine against the virus works: is it safe for children, the elderly and/or pregnant women? It will no doubt take some time to produce 7 billion doses, which is something that cannot be done overnight; but, first, we need to be sure that it works safely … for everyone!
A brighter future for cancer patients as survival rates soar
Advances in both oncology therapies and manufacturing technologies mean that a far greater number of cancer cases can now be diagnosed, treated and successfully managed.
Uniting innovation and sustainability in pharma
GEA directs its focus toward the juncture of sustainability and innovation, igniting positive transformation across our organization and the expansive pharmaceutical sector.
Insulin in the Diabetes War
The International Diabetes Federation (IDF) estimates that by 2030 there will be in excess of 550 million diabetics — or 10% of all the adults on the planet. World Health Organization figures suggest that, by then, diabetes deaths will have increased by two thirds.
The unsung heroes of global health and well-being
When we consider the concept of health, we generally think about being free from injury or illness. We might look at a person’s mental or physical condition, or delve more deeply into nutrition, exercise, sleep and the environment we live in. In recent times, vaccines and medicines have taken center stage as the world battles the ongoing pandemic. Yet, often behind the scenes and anonymous, a vast array of technologies and innovations are working hard, every day, to ensure that the food, drugs, water and energy that we use to stay well are safe, reliable and sustainable. At the heart of many of those processes – and supporting healthy living – is GEA equipment.
